Cynata Therapeutics Ltd (ASX: CYP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Cynata Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $70.21 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 143.28 million
Earnings per share -0.051
Dividend per share N/A
Year To Date Return -28.47%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

Cynata Therapeutics Ltd (ASX: CYP)
Latest News

CYP ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Cynata Therapeutics Ltd

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which has branded Cymerus.

CYP Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
22 Jul 2021 $0.49 $0.01 2.06% 20,564 $0.49 $0.49 $0.49
21 Jul 2021 $0.49 $-0.01 -2.04% 47,098 $0.49 $0.50 $0.48
20 Jul 2021 $0.49 $-0.01 -2.00% 48,120 $0.50 $0.50 $0.48
19 Jul 2021 $0.50 $-0.01 -1.96% 27,928 $0.53 $0.54 $0.50
16 Jul 2021 $0.51 $0.02 4.08% 160,954 $0.50 $0.51 $0.49
15 Jul 2021 $0.49 $-0.01 -2.02% 115,897 $0.50 $0.50 $0.48
14 Jul 2021 $0.50 $-0.01 -2.00% 134,580 $0.50 $0.50 $0.49
13 Jul 2021 $0.50 $-0.01 -1.98% 179,230 $0.51 $0.51 $0.50
12 Jul 2021 $0.51 $0.00 0.00% 160,265 $0.51 $0.52 $0.51
09 Jul 2021 $0.51 $-0.02 -3.85% 243,240 $0.52 $0.52 $0.50
08 Jul 2021 $0.52 $-0.01 -1.90% 218,830 $0.54 $0.54 $0.51
07 Jul 2021 $0.53 $0.01 1.92% 14,586 $0.53 $0.53 $0.53
06 Jul 2021 $0.52 $0.00 0.00% 143,185 $0.53 $0.53 $0.52
05 Jul 2021 $0.52 $-0.02 -3.74% 191,796 $0.54 $0.54 $0.52
02 Jul 2021 $0.54 $0.02 3.85% 545,553 $0.54 $0.56 $0.53
01 Jul 2021 $0.52 $0.02 3.96% 57,436 $0.52 $0.53 $0.51
30 Jun 2021 $0.51 $-0.01 -1.94% 456,179 $0.52 $0.53 $0.51
29 Jun 2021 $0.52 $0.01 1.98% 1,389,838 $0.51 $0.52 $0.50
28 Jun 2021 $0.51 $-0.02 -3.85% 600,067 $0.52 $0.52 $0.50
25 Jun 2021 $0.52 $-0.02 -3.70% 740,893 $0.54 $0.54 $0.51
24 Jun 2021 $0.54 $-0.02 -3.60% 537,303 $0.55 $0.55 $0.53
23 Jun 2021 $0.56 $0.01 1.82% 188,141 $0.55 $0.56 $0.54

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
30 Nov 2020 Paul Wotton Buy 300 $237,000
As advised by the company. Nature of change is not mentioned.
30 Nov 2020 Ross Macdonald Issued 1 $1,185,000
Issue of options.
30 Nov 2020 Geoffrey Brooke Issued 2 $1,580,000
Issue of options.
30 Nov 2020 Stewart Washer Issued 300 $237,000
Issue of options.
30 Nov 2020 Darryl Maher Issued 300 $237,000
Issue of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Paul K Wotton Non-Executive Director Jun 2016
Dr Wotton is the Chief Executive Officer of Obsidian Therapeutics, a leading synthetic biology company based in Cambridge, Massachusetts. Prior to this, he was the Founding President and CEO of Sigilon Inc. He was previously President and CEO of Ocata Therapeutics Inc. (NASDAQ: OCAT) guiding the company through a take-over by Astellas Pharma Inc., in a US$379 million all cash transaction. Prior to Ocata, Dr Wotton had served as President and CEO of Antares Pharma Inc. (NASDAQ: ATRS) since October 2008. Prior to joining Antares, Dr Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Dr Wotton held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr Wotton is a member of the Board and Governance Committee of Vericel Corporation, a US company developing autologous cellular therapies and a member of the board at PaxMedica where he is Chairman of the Compensation Committee. He was a member of the board of Veloxis Pharmaceuticals A/S and Chairman of the Compensation Committee, until its acquisition by Asahi Kasai in February 2020 in a $1.3 Billion all cash transaction. He is also past Chairman transaction. He is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. In 2014, he was named New Jersey EY Entrepreneur of the Year in Life Sciences.
Dr Ross Macdonald Chief Executive OfficerManaging Director Aug 2013
Dr Macdonald has over 33 years experience. His career history includes positions as Vice President of Business Development for Sinclair Pharmaceuticals Ltd (now Sinclair Pharma plc), a UK-based specialty pharmaceuticals company and Vice President, Corporate Development for Stiefel Laboratories Inc, the largest independent dermatology company in the world and acquired by GlaxoSmithKline in 2009 for Pound 2.25b. Dr Macdonald has also served as CEO of Living Cell Technologies Ltd, Vice President of Business Development of Connetics Corporation and Vice President of Research and Development of F H Faulding & Co Ltd. Dr Macdonald currently serves as a member of the Investment Committee of UniSeed Management Pty Ltd.
Mr Peter Webse Company Secretary May 2012
Mr Webse has over 28 years company secretarial experience and is the managing director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance and corporate advisory services.
Dr Geoffrey E.D Brooke Non-Executive DirectorNon-Executive Chairman May 2019
Dr Brooke has 30 years' experience in the healthcare,venture capital industries and has life sciences and financial knowledge. Dr Brooke is the founder and former Managing Director of two life sciences venture capital firms, GBS Ventures and Medvest Inc, and has been the lead investor of numerous healthcare companies. He is Chairman of Actinogen Medical Limited (ASX: ACW) and a non-executive director of Acrux Limited (ASX: ACR).
Dr Stewart James Washer Non-Executive Director Aug 2013
Dr Washer has over 27 years of CEO and board experience in medical technology and biotech companies. Dr Washer was previously a Senator with Murdoch University.
Dr Darryl Maher Non-Executive Director Jun 2020
Dr Maher have 23 years experience with CSL Limited. Dr Maher has had a career in pharmaceutical product development, most recently as the former Vice President of R&D and Medical Affairs at CSL Behring Australia where he was responsible for the development of multiple successful drug products from initiation through to clinical development and ultimately to commercialisation. Dr Maher undertook medical training, qualified as a specialist haematologist.
Kilian Kelly Chief Operating Officer
-
Suzanne Lipe Vice President Alliance Management
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 13,109,743 11.19%
Fujifilm Corporation 8,088,403 6.92%
BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient Drp> 4,192,431 3.58%
J P Morgan Nominees Australia Limited 3,754,341 3.21%
Citicorp Nominees Pty Limited 2,958,639 2.53%
John W King Nominees Pty Ltd 2,373,596 2.03%
National Nominees Limited 2,217,794 1.89%
Mal Washer Nominees Pty Ltd <Mal Washer Family A/C> 2,020,000 1.72%
Dr Ross Alexander Macdonald 2,000,000 1.71%
Brispot Nominees Pty Ltd <House Head Nominees A/C> 1,610,211 1.37%
Helium Management Pty Ltd <Helium S/F A/C> 1,360,366 1.16%
Dr Maksym Vodyanyk 1,191,658 1.02%
Mr Jon Nicolai Bjarnason & Mrs Rina Eghoje Bjarnason <Jarck Super Fund A/C> 825,000 0.70%
Riversdale Capital Funding Pty Ltd <The RCF A/C> 811,621 0.69%
Ms Kyoko Yukawa 800,000 0.68%
Tenbagga Resources Fund Pty Ltd <Tenbagga Family A/C> 771,847 0.66%
CM Cook Superannuation Pty Ltd <CM Cook Super Fund A/C> 700,000 0.60%
Neweconomy Com AU Nominees Pty Limited <900 Account> 682,781 0.58%
BNP Paribas Noms Pty Ltd <Drp> 674,489 0.58%
Crosswind Trustee Company Limited <Crosswind A/C> 600,000 0.51%

Profile

since

Note